Introduction
============

Fuchs endothelial corneal dystrophy (FECD) is characterized by the accumulation of focal excrescences called corneal guttae and the thickening of Descemet's membrane accompanied by corneal edema \[[@r1]\]. Progressive endothelial cell loss causes failure of the endothelial pump allowing the relative influx of aqueous humor into the cornea, causing epithelial and stromal edema and resulting in distorted vision. FECD exists as early and late onset forms; the late form usually appears between the fourth and fifth decades of life. Most cases are sporadic, but autosomal dominant inheritance has also been reported \[[@r2]\].

Worldwide prevalence of FECD varies widely. It is estimated to affect about 5% of the population over the age of 40 years in the United States \[[@r3]\]. In the isolated population of Tangier Island, approximately 50% of the population over the age of 50 years is affected with FECD \[[@r4]\]. There is a lack of precise data on the prevalence rate in India and the exact underlying genetic basis is largely unknown, but reports have substantiated a genetic basis \[[@r5]\]. The role of genetic factors is well recognized in FECD, and different variants of genes such as *COL8A2* (ID: 1296; OMIM: [120252](http://omim.org/entry/120252)), *SLC4A11* (ID: 83959; OMIM: [610206](http://omim.org/entry/610206)), *ZEB1* (ID: 6935; OMIM [613270](http://omim.org/entry/613270)), *TCF4* (ID: 6925; OMIM [602272](http://omim.org/entry/602272)); *AGBL1* (ID: 123624; OMIM [615496](http://omim.org/entry/615496)) show a disease association in a small proportion of patients with FECD.

Genome-wide linkage studies identified *collagen type VIII alpha 2* (*COL8A2;* 1p34.3-p32; OMIM: [120252](http://omim.org/entry/120252)) as responsible for early onset FECD \[[@r6],[@r7]\]. Type VIII collagen is the most important component of Descemet's membrane and composed of two α-1 chains and one α-2 chain. The role of type VIII collagen is unknown, but its association with endothelial cells may help in determining the cell phenotype. Several studies have reported *COL8A2* mutations in early onset FECD \[[@r6]-[@r8]\]. Late onset autosomal dominant- FECD (AD-FECD) has been mapped to three separate loci on chromosomes 13pTelq12 (FCD1), 18q21.2--21.3 (FCD2), and 5q33--35 (FCD3) \[[@r9]-[@r11]\], but no clear association has been established to date.

Involvement of *SLC4A11* (20p13, OMIM: [610206](http://omim.org/entry/610206)), which encodes a solute carrier family 4, member 11, also known as BTR1-bicarbonate transporter related protein 1, or NaBC1-sodium-borate cotransporter 1 \[[@r11]\], was reported in patients with FECD and later confirmed in several studies \[[@r5],[@r12]\]. The resulting mutant SLC4A11 proteins were also found to be defective in localization and turnover compared to the wild-type proteins \[[@r13]\].

Mutations in the *TCF8* gene, a transcription factor (10p11.22; OMIM [613270](http://omim.org/entry/613270)), have been reported in patients with late onset FECD \[[@r14]\]. *TCF8*, also known as zinc finger E-box binding homeobox 1 (*ZEB1*), encodes a zinc finger transcription factor, a two-pronged homeodomain protein that functions as a transcriptional enhancer as well as a repressor \[[@r15]\]. Pathogenic *ZEB1* mutations have been identified in posterior polymorphous corneal dystrophy-3 (PPCD3) \[[@r16]\], and later, they were also found to be associated with FECD \[[@r14]\].

The *TCF4* (18q21.2, OMIM [602272](http://omim.org/entry/602272)) gene is a member of the E-protein family of class I basic helix--loop--helix (bHLH) transcription factors \[[@r17]\]. A genome-wide association study (GWAS) identified several single nucleotide polymorphisms (SNPs) in the *TCF4* gene that included the SNP [rs613872](http://www.ncbi.nlm.nih.gov/snp/?term=rs613872), the first major genetic risk factor for FECD. Several studies have shown genetic variations within *TCF4* to be associated with FECD \[[@r17]-[@r19]\]. Of these variations, *TCF4* [rs613872](http://www.ncbi.nlm.nih.gov/snp/?term=rs613872) present in intron 3 was reported to be significantly associated with late onset FECD \[[@r17],[@r18],[@r20]\]. The present study was undertaken to identify known and unknown variations in the reported candidate and associated genes *COL8A2*, *SLC4A11*, and *ZEB1* and the *TCF4* SNP [rs613872](http://www.ncbi.nlm.nih.gov/snp/?term=rs613872) by screening Indian patients with FECD.

Methods
=======

Clinical examination
--------------------

A total of 82 patients (27 males and 55 females) diagnosed with FECD were recruited from the outpatient department of Rajendra Prasad Centre for Ophthalmic sciences (RPC), AIIMS and 143 age and sex matched controls from the general population during the period 2007--2012. The subjects at the time of recruitment were healthy except for visual problems in the FECD patients and their age ranged between 41 years to 82 years. The study adhered to the Declaration of Helsinki and the ARVO statement on human subjects and was approved by Institute Ethics Committee. In addition to undergoing a complete ophthalmic examination, all patients were examined under a slit-lamp and evaluated clinically using specular microscopy and ultrasonic pachymetry. FECD was diagnosed clinically based on the following criteria: the presence of central guttae changes, frequent morning blurring of vision, progressive disease, increased central corneal thickness (CCT; \>550 µm thickness), and decreased specular count (\<2000 cells/mm^2^). Histopathology and transmission electron microscopy (TEM) studies were performed on the host corneal buttons obtained from patients who underwent keratoplasty. Corneal button specimens in the case of penetrating keratoplasty and Descemet's membrane specimens in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) surgery preserved in formalin were obtained from the operation theater, cut into fine sections, stained with hematoxylin and eosin (H & E) stain, and evaluated under a light microscope (Nikon, Tokyo, Japan). The corneal tissues for TEM were immediately fixed in Karnovski fixative. Tissue samples were embedded in araldite after dehydration and clearing, and blocks were prepared. Sections were cut with a glass knife using an ultramicrotome (UC-6; Leica) and visualized under an electron microscope (Morgagni 268D; FEI Holland).

Study samples
-------------

A total of 82 patients diagnosed with FECD and 143 controls from the general population were recruited during the period 2007--2012. Five ml of peripheral blood samples were drawn by venipuncture in EDTA vials from all the participants after taking informed consent. Genomic DNA was extracted from the blood samples by the salting out method \[[@r21]\]. The DNA was stored at -20 degree centigrade till further use. Genomic DNA isolated from peripheral blood samples was processed for PCR amplification to screen the exons of *COL8A2, SLC4A11, TCF8* (82 patients and 100 controls), and the *TCF4* SNP (82 patients and 143 controls) using primers described previously \[[@r5],[@r7]\]. The cycling conditions were 7 min initial denaturation at 95 °C, followed by 35 cycles of 94 °C for 30 s, 58 °C /60 °C for 1 min, 72 °C for 1 min, and a final extension at 72 °C for 10 min. The reaction mixture of 25 μl was prepared using 200 ng genomic DNA, specific primers (0.5 μM each), MgCl~2~ (1.5 mM), deoxyribonucleotide triphosphates (dNTPs; 0.2 mM), 1× PCR buffer (Thermo, Wilmington, MA), and Taq polymerase (0.5 U; Roche) in a thermocycler (ABI 9700, Applied Biosystems \[ABI\], Foster City, CA). The PCR products were processed for gel purification using QIAmp gel extraction kits (Qiagen, GmBH, Hilden), and the purified PCR products were screened for sequence changes with Sanger sequencing. The amplified products were sequenced directly with BigDye Terminator Mix version 3.1 (ABI) according to the manufacturer's instructions and were then analyzed on an ABI-3100 Genetic Analyzer (ABI). Nucleotide sequences for the coding regions were compared with the nucleotide sequence of the published *SLC4A11* human cDNA ([NM_032034](http://www.ncbi.nlm.nih.gov/nuccore/NM_032034)), *ZEB1* human cDNA ([NM_030751](http://www.ncbi.nlm.nih.gov/nuccore/NM_030751)), *COL8A2* human cDNA ([NM_0052021](http://www.ncbi.nlm.nih.gov/nuccore/NM_0052021)), and *TCF4* human cDNA ([NM_003199](http://www.ncbi.nlm.nih.gov/nuccore/NM_003199)).

In silico analysis
------------------

Sorting Intolerant From Tolerant ([SIFT](http://sift.jcvi.org)) and MutationTaster tools were used to characterize the pathogenicity of the changes identified. SIFT predicts whether an amino acid substitution affects protein function, and the prediction is based on the degree of conservation of amino acid residues in sequence alignments derived from closely related sequences.

It gives a value as a score, and a score \<0.05 is considered potentially damaging. [MutationTaster](http://www.mutationtaster.org), a free, web-based application for rapid evaluation of the disease-causing potential of DNA sequence alterations, predicts the sequence variations to be disease causing. The probability of prediction, a value close to 1, indicates a high degree of accuracy for the prediction.

Statistical analysis
--------------------

The genotype and allele frequency were calculated for the patient and control groups, and the significance was tested with chi-square and Fisher's exact tests. Correlation of genotypes with parameters such as gender, age at onset, duration of the disease, CCT, and specular count was done through an unpaired Student *t* test using [GraphPad Prism](http://www.graphpad.com/) software. A 'p' value of less than 0.05 was considered significant.

Results
=======

The study patients underwent clinical and histopathological examinations and genetic evaluation for variations in *COL8A2*, *SLC4A11*, *ZEB1*, and *TCF4* ([rs613872](http://www.ncbi.nlm.nih.gov/snp/?term=rs613872)). The results obtained were correlated with gender, age at onset, presence of consanguinity, family history, CCT, and specular count.

Clinical profile
----------------

The patients in the study showed a mean age of onset of symptoms at 59.14±1.41 years and a male to female ratio of 1:1.5. Ultrasound pachymetry and specular microscopy showed increased corneal thickness (617.30±15.73 µm) and decreased endothelial count (1629±93.62 cells/mm^2^), respectively ([Table 1](#t1){ref-type="table"}). Histopathology confirmed FECD diagnosis in the patients who underwent keratoplasty. Light microscopy using H&E staining showed a marked increase in corneal and Descemet's membrane thickness ([Figure 1A,B](#f1){ref-type="fig"}) in addition to decreased endothelial cell counts. Electron microscopy study of the corneal buttons showed stromal thickening with severe disorganization and disruption of the lamellar pattern. Descemet's membrane showed disorganized bundles of banded collagen. Spindle-shaped wide-space collagen, typical of late onset FECD, was found in the posterior banded layer ([Figure 1D-F](#f1){ref-type="fig"}).

###### Gender wise comparison of clinical parameters in the FECD patients.

  **Clinical Parameters**   **Total (n=82)**   **Males (n=27)**   **Females (n=55)**   **P value**
  ------------------------- ------------------ ------------------ -------------------- -------------
  Specular count            1629±93.62         1675±131.4         1588±134.7           0.651
  CCT                       617.30±15.73       593.2±21.19        634.5±21.96          0.200
  Age at Onset              59.14±1.41         61.75±2.265        56.44±2.166          0.099
  Duration of Disease       4.37±0.718         5.71±1.108         3.50±0.917           0.135

Values shown are Mean±SEM

![Representative images of histopathology and TEM in FECD. **A**: Photomicrograph of hematoxylin and eosin staining (20X) reveals stromal edema with thickened Descemet's and retrocorneal membrane. **B**: Descemet's membrane thickening of the DSAEK specimen (40X). **C**: Photomicrograph of hematoxylin and eosin staining (20X) of a control. **D**: Transmission electron microscopy (TEM) showing Descemet's membrane of typical Fuchs endothelial corneal dystrophy (FECD). Four regions are distinguished: anterior banded, non-banded, posterior banded, and the fibrillar region (scale bar, 2 µm). **E**: Enlarged view of the posterior stroma with guttae-like deposits. **F**: Enlarged view of the stroma showing degenerative changes and guttae-like excrescences of spindle-shaped wide-space collagen (scale bar, 200 nm).](mv-v21-1252-f1){#f1}

Genetic profile
---------------

Consanguinity was seen in one family and a positive history in two families. The novel changes and variations associated with FECD are shown in [Figure 2](#f2){ref-type="fig"} and the in silico prediction in [Table 2](#t2){ref-type="table"}.

![Partial nucleotide sequence of the *ZEB1* and *TCF4* variations in FECD patients. Novel *ZEB1* changes identified in the study are shown in panels **A** to **D**. The *ZEB1* single nucleotide polymorphism (SNP) [rs220060](http://www.ncbi.nlm.nih.gov/snp/?term=rs220060) and the *TCF4* SNP rs613872 significantly associated with Fuchs endothelial corneal dystrophy (FECD) are shown in panels **E** and **F**. P=patient; C=control.](mv-v21-1252-f2){#f2}

###### Details of mutations and variations identified in FECD and their *in-silico* prediction.

  **Changes**        **Gene**   **Exon/ Intron**   **Cases (n=82)**   **Control (n=100)**   **P-value**    **SIFT Prediction**   **SIFT Score\*\***   **Mutation taster** **Prediction\***
  ------------------ ---------- ------------------ ------------------ --------------------- -------------- --------------------- -------------------- --------------------------------------
  **p.Glu733Lye**    ZEB1       Exon 7             1/82               NC                    NA             DAMAGING              0.01                 D (0.9999)
  **p.Ala818Val**    ZEB1       Exon 7             1/82               NC                    NA             tolerated             0.12                 D (0.9998)
  **p.Leu947stop**   ZEB1       Exon 8             1/82               NC                    NA             DAMAGING              0                    D (1.0)
  **p.Gln840Pro**    ZEB1       Exon 7             1/82               NC                    NA             tolerated             0.14                 D (0.9998)
  **p.Ser234Ser**    ZEB1       Exon 6             2/82               NC                    NA             tolerated             1                    D (0.9998)
  **rs220060**       ZEB1       Intron 5           \~24%(19/82)       4% (4/100)            **0.000743**   NA                    NA                   P (0.7116)
  **rs77516068**     ZEB1       Intron 3           \~3.0% (2/82)      NC                    NA             NA                    NA                   P (0.9999)
  **rs7918614**      ZEB1       Exon 2             \~10% (8/82)       11% (11/100)          0.8131         tolerated             1                    P (1.7600 )
  **rs161233**       ZEB1       Intron3            17% (13/82)        9% (9/100)            0.087          NA                    NA                   P (0.9999)
  **rs149166539**    ZEB1       Exon 6             \~3.0% (2/82)      NC                    NA             tolerated             1                    D (0.9999)
  **IVS2+276**       ZEB1       Intron 3           \~14% (11/82)      NC                    NA             NA                    NA                   P (0.9999)
  **rs613872**       TCF4       Intron 9           \~34% (28/82)      \~17% (25/143)        **0.0117**     NA                    NA                   P (0.9999)
  **rs75864656**     COL8A2     Exon 2             \~17% (14/82)      17% (17/100)          1.000          tolerated             0.62                 NA

\*\* SIFT value scores of '0' is most deleterious mutation, \<0.05 is potentially damaging and '1' is tolerated mutation. \* value close to 1 indicates high security of prediction. D: Disease causing; P: Polymorphism; NC: None of the control; NA: Not applicable

Direct sequencing of the *ZEB1* gene in the patients identified a novel nonsense p.Leu947stop mutation (1/82), two novel missense mutations, p.Glu733Lys (1/82) and p.Ala818Val (1/82), a novel synonymous mutation, p.Ser234Ser(2/82), and a novel variant at position IVS2+276 C/T in 11/82 of the patients. A reported nonsense mutation p.Gln840Pro was also found (1/82). In addition, SNPs p.Asp64Asp ([rs7918614](http://www.ncbi.nlm.nih.gov/snp/?term=rs7918614)) in exon 2, p.T232T ([rs149166539](http://www.ncbi.nlm.nih.gov/snp/?term=rs149166539)) in exon 6, and three intronic SNPs ([rs77516068](http://www.ncbi.nlm.nih.gov/snp/?term=rs77516068), [rs220060](http://www.ncbi.nlm.nih.gov/snp/?term=rs220060), and [rs161233](http://www.ncbi.nlm.nih.gov/snp/?term=rs161233)) were also identified. The polymorphisms [rs149166539](http://www.ncbi.nlm.nih.gov/snp/?term=rs149166539) (2/82), [rs77516068](http://www.ncbi.nlm.nih.gov/snp/?term=rs77516068) (2/82; not identified in any of the controls), and [rs161233](http://www.ncbi.nlm.nih.gov/snp/?term=rs161233) (13/82 in FECD; 9% controls) are being reported for the first time in FECD. The genotype frequency of AG in SNP [rs220060](http://www.ncbi.nlm.nih.gov/snp/?term=rs220060) in the patients with FECD was significantly high (24%; 19/82) compared to the controls (4%; 4/100; p=7.43×10^−4^) showing an association with late onset FECD. The frequency of [rs161233](http://www.ncbi.nlm.nih.gov/snp/?term=rs161233) genotype TG was 17% (13/82) in the patients with FECD and 9% (9/100) in the controls (p=0.087). Although a higher frequency was observed in patients for this SNP, a significant association was not observed.

The genotype frequency of the *TCF4* [rs613872](http://www.ncbi.nlm.nih.gov/snp/?term=rs613872) SNP represents a change A\>C with genotypes CC, CA, and AA. A higher frequency of the allele C was seen in the patients with FECD (17.07%; 28/82) compared to the controls (10.14%; 29/143; p=0.0393). The frequency of genotype CA was found to be 34.15% (28/82) in the patients with FECD and 17.48% (25/143) in the controls, showing the CA genotype was significantly associated (p=0.0117) with the disease.

The rs613872 genotype was compared with CCT, age at onset, duration of disease, and endothelium cell density ([Table 3](#t3){ref-type="table"}). The CA genotype was found to be significantly associated with decreased endothelial cell density (p=0.0259) compared to the AA genotype ([Table 3](#t3){ref-type="table"}; [Figure 3](#f3){ref-type="fig"}). No mutations were identified in *COL8A2* and *SLC4A11* except a previously reported SNP ([rs75864656](http://www.ncbi.nlm.nih.gov/snp/?term=rs75864656)) in the *COL8A2* gene that was present in equal frequency in the patients and the controls.

###### Association of TCF SNP rs613872 with specular count in FECD.

  **Clinical symptoms**     **Rs613872 AA genotype**   **Rs613872 AC genotype**   **p value**
  ------------------------- -------------------------- -------------------------- --------------
  **Specular count**        1733±107.3                 1239±181.6                 **0.0259\***
  **CCT**                   619.1±16.06                606.1±37.45                0.7378
  **Age at Onset**          58.32±1.493                60.64±3.835                0.4994
  **Duration of Disease**   3.488±0.634                6.300±1.756                0.0745

Values shown are Mean±S.E, \* p\<0.05.

![Difference in specular count between *TCF* rs613872 genotypes AA and AC as shown with an unpaired Student *t* test (p=0.0259, ≤0.05).](mv-v21-1252-f3){#f3}

Discussion
==========

FECD has a complex etiology with the involvement of genetic and environmental factors. Approximately 50% of FECD cases show familial clustering \[[@r22]\], and the disease generally follows an autosomal dominant pattern of inheritance \[[@r22],[@r23]\].

The fundamental pathologic feature is the abnormal assembly of collagen within the extracellular matrix \[[@r6]\]. In particular, the accumulation in the anterior layer of the Descemet's membrane during early fetal development \[[@r24]\] indicates that FECD is primarily a congenital disorder of collagen secretion and arrangement \[[@r6]\]. Final manifestation of the disease is variable and might depend on other genetic and environmental factors. Our TEM results are in accordance with those of a previous study \[[@r25]\] and suggest that the accumulation of large amounts of collagen in the anterior layer may be the primary pathologic attribute of the disease.

After *COL8A2* was identified in early onset FECD, several studies reported the L450W \[[@r2],[@r6],[@r26]\] and Q455V \[[@r8]\] mutations confirming its role in early onset FECD. In the present study, we did not find any *COL8A2* mutations in the patients from northern India, and our results are in agreement with a report on patients with FECD from southern India. Similarly, neither the present study nor a similar one from southern India documents any *SLC4A11* changes in patients with late onset FECD \[[@r27]\].

*ZEB1* was initially found to be associated with PPCD3 \[[@r16]\] and later with FECD \[[@r14]\] as well. ZEB1 is an E-box binding transcription factor involved in the differentiation and development of various tissues and is associated with hernias, hydroceles, and skeletal deformities \[[@r14],[@r28]\]. To date, the exact role of *ZEB1* in FECD pathogenesis has not been defined. Riazuddin et al. identified *ZEB1* pathogenic mutations in FECD, but other studies did not show significant association of *ZEB1* with the disease \[[@r29],[@r30]\].

Chung et al. showed that truncating *ZEB1* mutations due to a premature stop codon may lead to reduced protein production and impaired localization of the protein within the cell \[[@r31]\]. We found a novel nonsense mutation (p.Leu947 stop) in one patient in exon 8 that codes for the *ZEB1* nuclear localization signal (NLS) domain. The NLS is required for import of ZEB1 into the nucleus \[[@r31]\]. The p.Leu947 stop mutant protein, although abundant, may lack the NLS domain and remain exclusively in the cytoplasm due to impaired nuclear translocation, thus leading to haploinsufficiency.

In contrast, *ZEB1* missense mutations do not seem to affect the nuclear localization or alter the rate of protein production \[[@r31]\]. The FECD missense mutations documented to date lie in the conserved sites of the protein and are suggested to be hypomorphic; that is, they do not cause a severe disease phenotype as seen in PPCD \[[@r31]\]. The effects of these mutations are still unknown and may include protein regulation or signaling. The novel p.Glu733Lys and p.Ala818Val and the reported p.Gln840Pro missense mutations lie in the conserved regions and may be responsible for disease pathogenicity. In the mutation p.Ala818Val, replacement of alanine with valine might disrupt the alpha helix and affect the function of the protein. The p.Gln840Pro mutation identified in one patient in our study was earlier reported to be pathogenic in FECD \[[@r15]\]. SNPs found in the present study [rs7918614](http://www.ncbi.nlm.nih.gov/snp/?term=rs7918614) (equal frequency in patients and controls) and [rs220060](http://www.ncbi.nlm.nih.gov/snp/?term=rs220060) (significantly associated with the disease) are reported to be associated with PPCD \[[@r19],[@r28],[@r32]\] and Fuchs dystrophy \[[@r29],[@r30]\].

Substitutions involving amino acids or single nucleotide changes have the potential to affect protein function. Interpretation of the identified gene variations, whether they actually cause a disease or just confer susceptibility to it, is one of the greatest challenges encountered by investigators today. Many research tools are available but, unfortunately, may sometimes be misleading due to problems related to inconsistency and overall accuracy, especially in downstream experimental research \[[@r33]\].

*ZEB1*, which encodes a transcription factor, plays an important role in embryonic development as well as in disease-causing mechanisms such as tumor formation by downregulation of the genes involved in maintaining the epithelial phenotype of the cells \[[@r34],[@r35]\]. *ZEB1* has a critical role in epithelial-to-mesenchymal transition (EMT) and regulates several genes involved in EMT \[[@r36]\]. However, the function of *ZEB1* in the endothelial cells of the cornea is not known. Based on the identification of *ZEB1* mutations in the endothelial dystrophies, *ZEB1* may be involved in maintaining endothelial cell density and corneal transparency.

*TCF4* genetic variations are reported to be associated with FECD \[[@r17]-[@r19]\], of which *TCF4* SNP rs613872 was reported to be significantly associated with late onset FECD \[[@r4],[@r17],[@r18],[@r20],[@r37]\]. Our results are in accordance with prior studies and show an association with increased risk of Fuchs dystrophy. Although in silico tools predict this change to be a polymorphism, our study, along with others, has identified this SNP to be associated with late onset FECD. Other *TCF4* changes reported are a CTG intronic repeat expansion \[[@r38],[@r39]\] and the SNP [rs17089887](http://www.ncbi.nlm.nih.gov/snp/?term=rs17089887), which have shown a significant association with late onset FECD \[[@r39]\].

Individuals with two risk alleles of *TCF4* SNP rs613872 carry 30 times more chance of developing FECD compared to individuals who carry a single risk allele \[[@r17]\]. We did not identify any individuals with two risk alleles in our study, but the heterozygous genotype (CA) carrying a single risk allele showed significant association with FECD.

There is evidence the [rs613872](http://www.ncbi.nlm.nih.gov/snp/?term=rs613872) SNP is associated with CCT in FECD \[[@r40]\]. We did not find any correlation of [rs613872](http://www.ncbi.nlm.nih.gov/snp/?term=rs613872) with age at onset, gender, or CCT. However, endothelial cell density (specular count) was significantly associated with [rs613872](http://www.ncbi.nlm.nih.gov/snp/?term=rs613872) in the patients.

*TCF4* (also known as E2--2) is expressed in the developing corneal endothelium \[[@r17]\] and has a role in the downregulation of cell adhesion proteins such as E-cadherin that results in loss of cell polarity and may decrease endothelial cell density by inducing EMT \[[@r41]\]. The presence of the SNP rs613872 risk variant may alter the activity of *TCF4* thus regulating the endothelial cell density. To summarize, E2--2 proteins under normal conditions may promote EMT during injury, age-related damage, and stress to the cornea by downregulation of E-cadherin, and possibly by increasing the expression of *ZEB1*, which is a direct repressor of the E-cadherin promoter. Dysregulation of E2--2 possibly due to the presence of polymorphisms may reduce *ZEB1* expression and EMT in the cornea, thus decreasing the migration, proliferation, and replacement of the damaged corneal cells \[[@r42]\].

Novel mutations identified in the present study add to the repertoire of *ZEB1* mutations that cause Fuchs corneal dystrophies. These findings also suggest that a single nucleotide change may be linked to other variants and alter the resulting protein in such a way that the presentation of the resulting phenotype becomes highly variable.

To the best of our knowledge, this is the first report on screening of *ZEB1* mutations and *TCF4* SNP in patients with late onset FECD from India in which novel *ZEB1* variations and polymorphisms were identified. The *TCF4* rs613872 was found to be associated with decreased endothelial cell density, thus envisaging a plausible role for the two in FECD pathogenesis.
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